Abion Inc.
ABION Inc. operates as a pharmaceutical biotech Company in South Korea and internationally. The company develops anticancer therapeutic drugs, such as ABN401, a tyrosine kinase inhibitor that is in Phase II clinical trials for treating non-small cell lung cancer, as well as in Phase I clinical trial for breast cancer; ABN501, a human monoclonal antibody that targets claudin 3 for treating solid c… Read more
Abion Inc. (203400) - Net Assets
Latest net assets as of June 2025: ₩11.65 Billion KRW
Based on the latest financial reports, Abion Inc. (203400) has net assets worth ₩11.65 Billion KRW as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩43.41 Billion) and total liabilities (₩31.76 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩11.65 Billion |
| % of Total Assets | 26.84% |
| Annual Growth Rate | 23.02% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 221.95 |
Abion Inc. - Net Assets Trend (2016–2024)
This chart illustrates how Abion Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Abion Inc. (2016–2024)
The table below shows the annual net assets of Abion Inc. from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩28.13 Billion | +181.88% |
| 2023-12-31 | ₩9.98 Billion | -33.91% |
| 2022-12-31 | ₩15.10 Billion | -52.96% |
| 2021-12-31 | ₩32.10 Billion | +260.21% |
| 2020-12-31 | ₩-20.04 Billion | -81.90% |
| 2019-12-31 | ₩-11.01 Billion | -547.97% |
| 2018-12-31 | ₩2.46 Billion | -15.42% |
| 2017-12-31 | ₩2.91 Billion | -45.80% |
| 2016-12-31 | ₩5.36 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Abion Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 18969308076000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩14.32 Billion | 50.90% |
| Other Components | ₩236.55 Billion | 840.90% |
| Total Equity | ₩28.13 Billion | 100.00% |
Abion Inc. Competitors by Market Cap
The table below lists competitors of Abion Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
KLARABO SVERIGE AB
F:F5H
|
$75.13 Million |
|
Landec Corporation
F:LDE
|
$75.13 Million |
|
BOS L ZY 10
F:967
|
$75.14 Million |
|
Polymetals Resources Ltd
AU:POL
|
$75.17 Million |
|
Lanna Resources Public Company Limited
BK:LANNA
|
$75.08 Million |
|
Richmond International Travel & Tours Co Ltd
TWO:2743
|
$75.04 Million |
|
FULL HOUSE RES DL-0001
F:F4L
|
$75.02 Million |
|
CI Games SA
WAR:CIG
|
$75.00 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Abion Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 9,979,423,260 to 28,130,267,230, a change of 18,150,843,970 (181.9%).
- Net loss of 43,381,471,020 reduced equity.
- Share repurchases of 6,741,850,910 reduced equity.
- New share issuances of 6,741,850,910 increased equity.
- Other factors increased equity by 61,532,314,990.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-43.38 Billion | -154.22% |
| Share Repurchases | ₩6.74 Billion | -23.97% |
| Share Issuances | ₩6.74 Billion | +23.97% |
| Other Changes | ₩61.53 Billion | +218.74% |
| Total Change | ₩- | 181.88% |
Book Value vs Market Value Analysis
This analysis compares Abion Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.01x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 5.22x to 3.01x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩566.87 | ₩2960.00 | x |
| 2017-12-31 | ₩258.32 | ₩2960.00 | x |
| 2018-12-31 | ₩198.34 | ₩2960.00 | x |
| 2019-12-31 | ₩-887.65 | ₩2960.00 | x |
| 2020-12-31 | ₩-1598.29 | ₩2960.00 | x |
| 2021-12-31 | ₩1711.67 | ₩2960.00 | x |
| 2022-12-31 | ₩801.28 | ₩2960.00 | x |
| 2023-12-31 | ₩453.07 | ₩2960.00 | x |
| 2024-12-31 | ₩982.29 | ₩2960.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Abion Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -154.22%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5710.46%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 2.27x
- Recent ROE (-154.22%) is above the historical average (-173.72%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -143.20% | -201.62% | 0.29x | 2.41x | ₩-8.22 Billion |
| 2017 | -325.44% | -517.68% | 0.22x | 2.87x | ₩-9.75 Billion |
| 2018 | -346.96% | -2291.13% | 0.05x | 3.21x | ₩-8.78 Billion |
| 2019 | 0.00% | -1155.51% | 0.13x | 0.00x | ₩-13.11 Billion |
| 2020 | 0.00% | -525.41% | 0.15x | 0.00x | ₩-8.47 Billion |
| 2021 | -169.03% | -3311.51% | 0.04x | 1.39x | ₩-57.47 Billion |
| 2022 | -131.95% | -794.94% | 0.10x | 1.60x | ₩-21.44 Billion |
| 2023 | -292.71% | -2292.30% | 0.03x | 4.48x | ₩-30.21 Billion |
| 2024 | -154.22% | -5710.46% | 0.01x | 2.27x | ₩-46.19 Billion |
Industry Comparison
This section compares Abion Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Abion Inc. (203400) | ₩11.65 Billion | -143.20% | 2.73x | $75.09 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |